Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2014 1
2015 2
2016 1
2017 2
2018 9
2019 4
2020 2
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA, Chen W, Dubois SP, Daenthanasanmak A, Müller JR, Reid R, Waldmann TA, Santi DV. Hangasky JA, et al. Among authors: daenthanasanmak a. J Immunother Cancer. 2022 Jan;10(1):e004104. doi: 10.1136/jitc-2021-004104. J Immunother Cancer. 2022. PMID: 35101947 Free PMC article.
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.
Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, Bryant B, Petrus MN, Bachy E, Huang DW, Yang Y, Green PL, Hasegawa H, Maeda M, Goto H, Endo T, Yokota T, Hatanaka KC, Hatanaka Y, Tanaka S, Matsuno Y, Yang Y, Hashino S, Teshima T, Waldmann TA, Staudt LM, Nakagawa M. Ishio T, et al. Among authors: daenthanasanmak a. Blood. 2022 Mar 10;139(10):1541-1556. doi: 10.1182/blood.2021012734. Blood. 2022. PMID: 34818414 Free PMC article.
EGR1 Addiction in Diffuse Large B-cell Lymphoma.
Kimpara S, Lu L, Hoang NM, Zhu F, Bates PD, Daenthanasanmak A, Zhang S, Yang DT, Kelm A, Liu Y, Li Y, Rosiejka A, Kondapelli A, Bebel S, Chen M, Waldmann TA, Capitini CM, Rui L. Kimpara S, et al. Among authors: daenthanasanmak a. Mol Cancer Res. 2021 Aug;19(8):1258-1269. doi: 10.1158/1541-7786.MCR-21-0267. Epub 2021 May 12. Mol Cancer Res. 2021. PMID: 33980611 Free PMC article.
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.
Chatterjee S, Daenthanasanmak A, Chakraborty P, Wyatt MW, Dhar P, Selvam SP, Fu J, Zhang J, Nguyen H, Kang I, Toth K, Al-Homrani M, Husain M, Beeson G, Ball L, Helke K, Husain S, Garrett-Mayer E, Hardiman G, Mehrotra M, Nishimura MI, Beeson CC, Bupp MG, Wu J, Ogretmen B, Paulos CM, Rathmell J, Yu XZ, Mehrotra S. Chatterjee S, et al. Among authors: daenthanasanmak a. Cell Metab. 2018 Jan 9;27(1):85-100.e8. doi: 10.1016/j.cmet.2017.10.006. Epub 2017 Nov 9. Cell Metab. 2018. PMID: 29129787 Free PMC article.
Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation.
Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O'Mahony A, Walton K, Reff J, Horna P, Sagatys EM, Lee MC, Singer J, Chang YJ, Liu C, Pidala J, Anasetti C, Yu XZ. Betts BC, et al. Among authors: daenthanasanmak a. Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1582-1587. doi: 10.1073/pnas.1712452115. Epub 2018 Jan 30. Proc Natl Acad Sci U S A. 2018. PMID: 29382747 Free PMC article.
Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease.
Sofi MH, Wu Y, Schutt SD, Dai M, Daenthanasanmak A, Heinrichs Voss J, Nguyen H, Bastian D, Iamsawat S, Selvam SP, Liu C, Maulik N, Ogretmen B, Jin J, Mehrotra S, Yu XZ. Sofi MH, et al. Among authors: daenthanasanmak a. J Clin Invest. 2019 May 2;129(7):2760-2774. doi: 10.1172/JCI122899. J Clin Invest. 2019. PMID: 31045571 Free PMC article.
25 results